Anti-Blood Cancer Compound Library

Sizes available: 

10 mM *30µl, 10 mM *50µl, 10 mM *100µl, 2*10 mM *100µl, 10 mM *250µl

Please contact us for price or customized libraries!

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 2368 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research. MCE Anti-Blood Cancer Compound Library can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 2307 compounds supplied in 10 mM solution, 59 compounds supplied in 2 mM solution and 2 compounds supplied in 3 mg/mL solution. For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.